Cargando…
C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice
BACKGROUND: We have demonstrated that vaccination with pDNA encoding cysteine proteinase Type II (CPA) and Type I (CPB) with its unusual C-terminal extension (CTE) can partially protect BALB/c mice against cutaneous leishmanial infection. Unfortunately, this protection is insufficient to completely...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134432/ https://www.ncbi.nlm.nih.gov/pubmed/21765963 http://dx.doi.org/10.1371/journal.pntd.0001236 |
_version_ | 1782207986915082240 |
---|---|
author | Doroud, Delaram Zahedifard, Farnaz Vatanara, Alireza Taslimi, Yasaman Vahabpour, Rouholah Torkashvand, Fatemeh Vaziri, Behrooz Rouholamini Najafabadi, Abdolhossein Rafati, Sima |
author_facet | Doroud, Delaram Zahedifard, Farnaz Vatanara, Alireza Taslimi, Yasaman Vahabpour, Rouholah Torkashvand, Fatemeh Vaziri, Behrooz Rouholamini Najafabadi, Abdolhossein Rafati, Sima |
author_sort | Doroud, Delaram |
collection | PubMed |
description | BACKGROUND: We have demonstrated that vaccination with pDNA encoding cysteine proteinase Type II (CPA) and Type I (CPB) with its unusual C-terminal extension (CTE) can partially protect BALB/c mice against cutaneous leishmanial infection. Unfortunately, this protection is insufficient to completely control infection without booster injection. Furthermore, in developing vaccines for leishmaniasis, it is necessary to consider a proper adjuvant and/or delivery system to promote an antigen specific immune response. Solid lipid nanoparticles have found their way in drug delivery system development against intracellular infections and cancer, but not Leishmania DNA vaccination. Therefore, undefined effect of cationic solid lipid nanoparticles (cSLN) as an adjuvant in enhancing the immune response toward leishmanial antigens led us to refocus our vaccine development projects. METHODOLOGY/PRINCIPAL FINDINGS: Three pDNAs encoding L. major cysteine proteinase type I and II (with or without CTE) were formulated by cSLN. BALB/c mice were immunized twice by 3-week interval, with cSLN-pcDNA-cpa/b, pcDNA-cpa/b, cSLN-pcDNA-cpa/b(-CTE), pcDNA-cpa/b(-CTE), cSLN, cSLN-pcDNA and PBS. Mice vaccinated with cSLN-pcDNA-cpa/b(-CTE) showed significantly higher levels of parasite inhibition related to protection with specific Th1 immune response development, compared to other groups. Parasite inhibition was determined by different techniques currently available in exploration vacciation efficacy, i.e., flowcytometry on footpad and lymph node, footpad caliper based measurements and imaging as well as lymph node microtitration assay. Among these techniques, lymph node flowcytometry was found to be the most rapid, sensitive and easily reproducible method for discrimination between the efficacy of vaccination strategies. CONCLUSIONS/SIGNIFICANCE: This report demonstrates cSLN's ability to boost immune response magnitude of cpa/cpb(-CTE) cocktail vaccination against leishmaniasis so that the average parasite inhibition percent could be increased significantly. Hence, cSLNs can be considered as suitable adjuvant and/or delivery systems for designing third generation cocktail vaccines. |
format | Online Article Text |
id | pubmed-3134432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-31344322011-07-15 C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice Doroud, Delaram Zahedifard, Farnaz Vatanara, Alireza Taslimi, Yasaman Vahabpour, Rouholah Torkashvand, Fatemeh Vaziri, Behrooz Rouholamini Najafabadi, Abdolhossein Rafati, Sima PLoS Negl Trop Dis Research Article BACKGROUND: We have demonstrated that vaccination with pDNA encoding cysteine proteinase Type II (CPA) and Type I (CPB) with its unusual C-terminal extension (CTE) can partially protect BALB/c mice against cutaneous leishmanial infection. Unfortunately, this protection is insufficient to completely control infection without booster injection. Furthermore, in developing vaccines for leishmaniasis, it is necessary to consider a proper adjuvant and/or delivery system to promote an antigen specific immune response. Solid lipid nanoparticles have found their way in drug delivery system development against intracellular infections and cancer, but not Leishmania DNA vaccination. Therefore, undefined effect of cationic solid lipid nanoparticles (cSLN) as an adjuvant in enhancing the immune response toward leishmanial antigens led us to refocus our vaccine development projects. METHODOLOGY/PRINCIPAL FINDINGS: Three pDNAs encoding L. major cysteine proteinase type I and II (with or without CTE) were formulated by cSLN. BALB/c mice were immunized twice by 3-week interval, with cSLN-pcDNA-cpa/b, pcDNA-cpa/b, cSLN-pcDNA-cpa/b(-CTE), pcDNA-cpa/b(-CTE), cSLN, cSLN-pcDNA and PBS. Mice vaccinated with cSLN-pcDNA-cpa/b(-CTE) showed significantly higher levels of parasite inhibition related to protection with specific Th1 immune response development, compared to other groups. Parasite inhibition was determined by different techniques currently available in exploration vacciation efficacy, i.e., flowcytometry on footpad and lymph node, footpad caliper based measurements and imaging as well as lymph node microtitration assay. Among these techniques, lymph node flowcytometry was found to be the most rapid, sensitive and easily reproducible method for discrimination between the efficacy of vaccination strategies. CONCLUSIONS/SIGNIFICANCE: This report demonstrates cSLN's ability to boost immune response magnitude of cpa/cpb(-CTE) cocktail vaccination against leishmaniasis so that the average parasite inhibition percent could be increased significantly. Hence, cSLNs can be considered as suitable adjuvant and/or delivery systems for designing third generation cocktail vaccines. Public Library of Science 2011-07-12 /pmc/articles/PMC3134432/ /pubmed/21765963 http://dx.doi.org/10.1371/journal.pntd.0001236 Text en Doroud et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Doroud, Delaram Zahedifard, Farnaz Vatanara, Alireza Taslimi, Yasaman Vahabpour, Rouholah Torkashvand, Fatemeh Vaziri, Behrooz Rouholamini Najafabadi, Abdolhossein Rafati, Sima C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice |
title | C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice |
title_full | C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice |
title_fullStr | C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice |
title_full_unstemmed | C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice |
title_short | C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice |
title_sort | c-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against leishmania major in balb/c mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134432/ https://www.ncbi.nlm.nih.gov/pubmed/21765963 http://dx.doi.org/10.1371/journal.pntd.0001236 |
work_keys_str_mv | AT dorouddelaram cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice AT zahedifardfarnaz cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice AT vatanaraalireza cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice AT taslimiyasaman cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice AT vahabpourrouholah cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice AT torkashvandfatemeh cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice AT vaziribehrooz cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice AT rouholamininajafabadiabdolhossein cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice AT rafatisima cterminaldomaindeletionenhancestheprotectiveactivityofcpacpbloadedsolidlipidnanoparticlesagainstleishmaniamajorinbalbcmice |